FDA Approval Alert: The Need-to-Know | Amivantamab/Chemotherapy in EGFR-Mutated NSCLC

In September 2024, the FDA approved amivantamab-vmjw plus carboplatin and pemetrexed for patients with locally advanced or metastatic non–small cell lung cancer who have EGFR exon 19 deletions or exon 21 L858R substitution mutations following progression on or after treatment with an EGFR tyrosine kinase inhibitor.